Trends in drug prescriptions to diabetic patients from 2000 to 2008 in Italy's Lombardy Region: A large population-based study

Diabetes Research and Clinical Practice

Volumn 93, Issue 1, 2011, Pages 123-130

  Baviera, Marta ^a   Monesi, Lara ^a   Marzona, Irene ^a   Avanzini, Fausto ^a   Monesi, Gabriella ^b   Nobili, Alessandro ^a   Tettamanti, Mauro ^a   Riva, Emma ^a   Cortesi, Laura ^a   Bortolotti, Angela ^c   Fortino, Ida ^c   Merlino, Luca ^c   Fontana, Giancarlo ^c   Roncaglioni, Maria Carla ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b S MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

^c Regional Health Ministry   (Italy)

Author keywords

Antidiabetic drugs; Cardiovascular medications; Diabetes mellitus; Prescribing trends

Indexed keywords

ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BIGUANIDE DERIVATIVE; CARDIOVASCULAR AGENT; GLITAZONE DERIVATIVE; INSULIN DERIVATIVE; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA;

ADULT; AGED; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC PATIENT; FEMALE; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; POPULATION RESEARCH; PRACTICE GUIDELINE; PRESCRIPTION; TREND STUDY;

DIABETES MELLITUS; DRUG PRESCRIPTIONS; DRUG UTILIZATION; HUMANS; HYPOGLYCEMIC AGENTS; HYPOLIPIDEMIC AGENTS; ITALY; METFORMIN; PLATELET AGGREGATION INHIBITORS; SULFONYLUREA COMPOUNDS;

EID: 79960557423     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2011.05.004     Document Type: Article

References (36)

1. Zimmet P., Alberti K.G.M.M., Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001, 414:782-787.
2. Wild S., Roglic G., Green A., Sicree R., King H. Global prevalence of diabetes. Estimates for the year 2000 and projections for 2030. Diabetes Care 2004, 27:1047-1053.
3. World Health Organization Diabetes fact sheet (312) 2006, World Health Organization, Geneva. http://www.who.int/mediacentre/factsheets/fs312/en/index.html.
4. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352:837-853.
5. O'Brein J., Shomphe L.A., Kavanach P., Raggio G., Caro J.J. Direct medical costs of complications resulting from type 2 diabetes in the US. Diabetes Care 1998, 21:1122-1128.
6. Haffner S.M., Lehto S., Rönnemaa T., Pyörälä K., Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998, 339:229-234.
7. Miettinen H., Lehto S., Salomaa V., Mähönen M., Niemelä M., Haffner S.M., et al. Impact of diabetes on mortality after the first myocardial infarction. The FINMONICA Myocardial Infarction Register Study Group. Diabetes Care 1998, 21:69-75.
8. American Diabetes Association Standards of medical care in diabetes-2008. Diabetes Care 2008, 31(Suppl. 1):S12-S54.
9. International Diabetes Federation. Global guidelines for Type 2 Diabetes; August 2005. http://www.idf.org/home/index.cfm%3Funode=B7462CCB-3A4C-472C-80E4-710074D74AD3.
10. Associazione Medici Diabetologi (AMD), Società Italiana di Diabetologia (SID), Diabete Italia Standard italiani per la cura del diabete mellito. Linee. guida e raccomandazioni 2007, Infomedica Srl, Torino.
11. UK Prospective Diabetes Study (UKPDS) Group Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998, 352:854-865.
12. Ryden L., Standl E., Bartnik M., Van den Berghe G., Betteridge J., de Boer M.-J., et al. The task force on diabetes and cardiovascular diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD) Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. Eur Heart J 2007, 28:88-136.
13. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998, 317:703-713. UK Prospective Diabetes Study Group.
14. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000, 355:253-259. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators.
15. Dahlöf B., Devereux R.B., Kjeldsen S.E., Julius S., Beevers G., de Faire U., et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002, 359:995-1003.
16. MCR/BHF heart protection study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial. Lancet 2003, 361:2005-2016. Heart Protection Study Collaborative Group.
17. Costa J., Borges M., David C., Vaz Carniero A. Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomized controlled trials. BMJ 2006, 10.1136/bmj.38793.468449.AE.
18. Bakris G.L., Williams M., Dworkin L., Elliott W.J., Epstein M., Toto R., et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis 2000, 36:646-661.
19. Cohen F.J., Conklin J.E., Neslusan C.A., Song X. Recent antihyperglycemic prescribing trends for U.S. privately insured patients with type 2 diabetes. Diabetes Care 2003, 26:1847-1851.
20. Walley T., Hughes D., Kendall H. Trends and influences on use of antidiabetic drugs in England, 1992-2003. Pharmacoepidemiol Drug Saf 2005, 14:769-773.
21. Melander A., Folino-Gallo P., Walley T., Schwabe U., Groop P.H., Klaukka T., et al. Utilisation of antihyperglycaemic drugs in ten European countries: different developments and different levels. Diabetologia 2006, 49:2024-2029.
22. Lub R., Denig P., van den Berg P., Hoogenberg K., de Jong-van den Berg L.T.W. The impact of the new insights and revised practice guidelines on prescribing drugs in the treatment of type 2 diabetes mellitus. Br J Clin Pharmacol 2006, 62:660-665.
23. Secnik Boyc K., Yurgin N., Lage M.J. Trends in the prescription of antidiabetic medications in France: evidence from primary care physicians. Adv Ther 2007, 24:803-813.
24. Yurgin N., Secnik K., Lage M.J. Antidiabetic prescriptions and glycemic control in german patients with type 2 diabetes mellitus: a retrospective database study. Clin Ther 2007, 29:316-325.
25. Alexander G.C., Sehgal N.L., Moloney R.M., Stafford R.S. National trends in treatment of type 2 diabetes mellitus, 1194-2007. Arch Intern Med 2008, 168:2088-2094.
26. Filion K.B., Joseph L., Boivin J.F., Suissa S., Brophy J.M. Trends in the prescription of antidiabetic medications in the United Kingdom: a population-based analysis. Pharmacoepidemiol Drug Saf 2009, 18:973-976.
27. Mazzaglia G., Yurgin N., Boye K.S., Trifirò G., Cottrell S., Allen E., et al. Prevalence and antihyperglycemic prescribing trends for patients with type 2 diabetes in Italy: a 4-year retrospective study from national primary care data. Pharmacol Res 2008, 57:358-363.
28. CINECA Osservatorio ARNO Diabete-Analisi di dieci anni di prescrizioni. Rapporto 2007; vol XI.
29. Bennet K.E., Williams D., Feely J. Under-prescribing of cardiovascular therapies for diabetes in primary care. Eur J Clin Pharmacol 2003, 58:835-841.
30. Shah B.R., Mamdani M., Jaakkimainen L., Hux J.E. Risk modification for diabetic patients are other risk factors treated as diligently as glicemia?. Can J Clin Pharmacol 2004, 11:e239-e244.
31. Mann D.M., Woodward M., Ye F., Krousel-Wood M., Muntner P. Trends in medication use among US adults with diabetes mellitus: glycemic control at the expence of controlling cardiovascular risk factors. Arch Intern Med 2009, 169:1718-1720.
32. Gnavi R., Karaghiosoff L., Balzi D., Barchielli A., Canova C., Demaria M., et al. Diabetes prevalence estimated using a standard algorithm based on electronic health data in various areas of Italy. Epidemiol Prev 2008, 32(Suppl. 3):15-21.
33. Brocco S., Visentin C., Fedeli U., Schievano E., Avogaro A., Andretta M., et al. Monitoring the occurrence of diabetes mellitus and its major complications: the combined use of different administrative databases. Cardiovasc Diabetol 2007, 6:5. 10.1186/1474-2840-6-5.
34. Lamberts E.J.F., Hijpels G., Welschen L.M.C., Hugtenburg G., Dekker J.M., Souverein P.C., et al. Long term patterns of use after initiation of oral antidiabetic drug therapy. Pharmacoepidemiol Drug Saf 2010, 10.1002/pds.2089.
35. Montori V.M., Fernández-Balsells M. Glycemic control in type 2 diabetes: time for an evidence-based about-face?. Ann Intern Med 2009, 150:803-808.
36. American Diabetes Association Diagnosis and classification of diabetes mellitus. Diabetes Care 2005, 28(Suppl. 1):537-542.